Study #2015-0158
A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of FORE8394 in Patients with Advanced, Unresectable Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
FORE8394
Description
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Unresectable Solid Tumors, BRAF-mutated Tumors
Study phase:
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.